Insulet

PODD

Market cap $14B

Insulet Corp. Stock Falls After Voluntary Medical Device Correction Reveals Omnipod 5 Insulin-Leakage Defect Affecting Thousands of Pods NEW YORK, April 15, 2026 /PRNewswire/ -- Insulet Corp. (NASDAQ: PODD) shares dropped approximately 6.9% after the Company filed an 8-K on March 12, 2026, disclosing a voluntary medical device correction covering Omnipod 5 insulin pods due to a design defect that could cause insulin leakage -- a defect linked to eighteen serious adverse events. Shareholders who lost money on their PODD investment are encouraged to submit their information here.

NEW YORK, April 14, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Insulet Corporation (“Insulet” or the “Company”) (NASDAQ: PODD).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

Investors interested in Medical - Products stocks are likely familiar with Phibro Animal Health (PAHC) and Insulet (PODD). But which of these two stocks offers value investors a better bang for their buck right now?

NEW YORK, April 9, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Insulet Corporation ("Insulet" or the "Company") (NASDAQ: PODD).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.

NEW YORK, April 07, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Insulet Corporation (“Insulet” or the “Company”) (NASDAQ: PODD). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

New York, New York--(Newsfile Corp. - April 6, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into Insulet Corporation (NASDAQ: PODD) ("Insulet Corporation") concerning potential violations of the federal securities laws. During that same February 18 earnings call, McEvoy stated that "strong clinical evidence and real-world outcomes continue to earn prescriber and patient confidence" and described Omnipod 5 as the "favorite pump" for both type-1 and type-2 users in 2025.

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

NEW YORK, April 2, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Insulet Corporation ("Insulet" or the "Company") (NASDAQ: PODD). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.

Insulet Corp. Stock Falls After Voluntary Medical Device Correction Reveals Omnipod 5 Insulin-Leakage Defect Affecting Thousands of Pods NEW YORK, April 1, 2026 /PRNewswire/ -- Insulet Corp. (NASDAQ: PODD) shares dropped approximately 6.9% after the Company filed an 8-K on March 12, 2026, disclosing a voluntary medical device correction covering Omnipod 5 insulin pods due to a design defect that could cause insulin leakage -- a defect linked to eighteen serious adverse events. Shareholders who lost money on their PODD investment are encouraged to submit their information here.

ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced it will report financial results for the first quarter of 2026 on Wednesday, May 6, 2026, before the opening of the financial markets. In connection with the release, management will host a conference call that day at 8:00 a.m. (Eastern Time). The link to the live call will be available on the Inves.